Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
BEIGENE, LTD. currently manages a portfolio with 6 pending office actions. These actions are spread across 6 distinct examiners, meaning no two pending actions are currently assigned to the same person. This distribution occurs within the Biotechnology & Pharmaceuticals technology area, a field often characterized by complex examination requirements. The pending office actions are located across 3 distinct art units, suggesting that while the examiners are diverse, the technical focus is grouped into specific clusters.
Ismail, Rehana is the busiest examiner for the portfolio, holding 1 pending office action. Because every one of the distinct examiners also holds a pending office action, the workload is evenly distributed across the individual examiners. For practitioners, this means addressing the 3 different art unit environments while managing the distinct examiner relationships. The presence of the 6 pending office actions indicates the current level of ongoing interaction with the patent office in the biotechnology sector. Maintaining consistency across the various art units is a key consideration for the prosecution strategy in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.2% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926544 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | KOSACK, JOSEPH R | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18934390 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ISMAIL, REHANA | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
| 17612056 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18934390 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ISMAIL, REHANA | — | §112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18926544 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | KOSACK, JOSEPH R | — | §102§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18825776 | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | SHTERENGARTS, SAMANTHA L | — | §112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112 | Final Rejection | — | Pending | Jan 13, 2023 |
| 17612056 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | CREWS, JARET JAMES | 1691 | §112 | Non-Final OA | — | Pending | Nov 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial